Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) and TG Therapeutics (NASDAQ:TGTX – Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.
Valuation & Earnings
This table compares Aurinia Pharmaceuticals and TG Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $283.05 million | 7.50 | $287.20 million | $2.29 | 6.97 |
| TG Therapeutics | $616.29 million | 13.32 | $447.18 million | $2.74 | 19.57 |
Insider and Institutional Ownership
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Aurinia Pharmaceuticals has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
Profitability
This table compares Aurinia Pharmaceuticals and TG Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | 100.84% | 26.11% | 19.89% |
| TG Therapeutics | 55.22% | 73.49% | 34.14% |
Analyst Recommendations
This is a summary of current ratings and price targets for Aurinia Pharmaceuticals and TG Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 3 | 2 | 1 | 2.67 |
| TG Therapeutics | 2 | 1 | 6 | 0 | 2.44 |
Aurinia Pharmaceuticals presently has a consensus price target of $17.67, indicating a potential upside of 10.76%. TG Therapeutics has a consensus price target of $63.00, indicating a potential upside of 17.49%. Given TG Therapeutics’ higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Aurinia Pharmaceuticals.
Summary
TG Therapeutics beats Aurinia Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
